Vemurafenib-induced pancreatitis in a patient with recurrent hairy cell leukaemia.

BMJ Case Rep

Division of Hematology-Oncology, Department of Medicine, Northwell Health, Manhasset, New York, USA

Published: September 2020

Recent studies have shown that BRAF inhibitors, such as vemurafenib, are effective in inducing long periods of remission in relapsed hairy cell leukaemia. Acute pancreatitis is one of the rare complications that is reported with vemurafenib use. As severe pancreatitis can be life threatening, physicians should be vigilant of this side effect and promptly treat patients that develop clinical signs and symptoms while receiving vemurafenib. We present an interesting case of vemurafenib-induced pancreatitis that not only resolved but also did not recur after reintroduction of the drug at a reduced dose.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7490934PMC
http://dx.doi.org/10.1136/bcr-2020-236073DOI Listing

Publication Analysis

Top Keywords

vemurafenib-induced pancreatitis
8
hairy cell
8
cell leukaemia
8
pancreatitis patient
4
patient recurrent
4
recurrent hairy
4
leukaemia studies
4
studies braf
4
braf inhibitors
4
inhibitors vemurafenib
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!